SAN DIEGO --(BUSINESS WIRE)--May 7, 2026-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2026 and reaffirmed financial guidance for the year ending December 31, 2026.
SAN DIEGO --(BUSINESS WIRE)--Apr. 29, 2026-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: BofA Securities 2026 Health Care Conference on
First and only commercially available AID technology for pregnancy use in the U.S. SAN DIEGO --(BUSINESS WIRE)--Apr. 27, 2026-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that the United States Food and Drug Administration
SAN DIEGO --(BUSINESS WIRE)--Apr. 2, 2026-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2026 results after the financial markets close on Thursday, May 7, 2026.
Tandem Diabetes Care expands connected-care ecosystem by adding Android platform SAN DIEGO --(BUSINESS WIRE)--Mar. 4, 2026-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world’s smallest, durable
SAN DIEGO --(BUSINESS WIRE)--Feb. 25, 2026-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “notes”) in a private placement
SAN DIEGO --(BUSINESS WIRE)--Feb. 23, 2026-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of its Convertible
SAN DIEGO --(BUSINESS WIRE)--Feb. 19, 2026-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2025 and provided its financial guidance for the year ending
SAN DIEGO --(BUSINESS WIRE)--Feb. 12, 2026-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: Citi’s 2026 Unplugged MedTech and Life Sciences
SAN DIEGO --(BUSINESS WIRE)--Jan. 8, 2026-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2025 results after the financial markets close on Thursday, February 19, 2026 .
SAN DIEGO --(BUSINESS WIRE)--Dec. 18, 2025-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM) a leading insulin delivery and diabetes technology company, today announced availability of the Tandem t:slim mobile application for Android and iOS users in Canada .
SAN DIEGO --(BUSINESS WIRE)--Nov. 12, 2025-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025 . Ms.
By adding compatibility with the Android platform, Tandem Mobi is expanding its connected-care ecosystem SAN DIEGO --(BUSINESS WIRE)--Nov. 10, 2025-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that the U.S.
SAN DIEGO --(BUSINESS WIRE)--Nov. 6, 2025-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2025 and reaffirmed full year 2025 guidance.
Certification affirms Tandem’s company-wide commitment to cybersecurity, data protection, and operational integrity SAN DIEGO --(BUSINESS WIRE)--Nov. 4, 2025-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it achieved ISO/IEC
SAN DIEGO --(BUSINESS WIRE)--Oct. 31, 2025-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: Stifel 2025 Healthcare Conference on Tuesday,
Tandem Diabetes Care begins global commercial rollout of t:slim X2 pump integration with the FreeStyle Libre 3 Plus CGM sensor, expanding choice and personalization for people living with diabetes worldwide SAN DIEGO --(BUSINESS WIRE)--Oct. 29, 2025-- Tandem Diabetes Care, Inc .
SAN DIEGO --(BUSINESS WIRE)--Oct. 2, 2025-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2025 results after the financial markets close on Thursday, November 6, 2025 .
SAN DIEGO --(BUSINESS WIRE)--Sep. 29, 2025-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and
This sub-analysis is the first study to evaluate AID outcomes for people with type 2 diabetes using the Center for Medicare and Medicaid Services (CMS) criteria for insulin pump coverage. SAN DIEGO --(BUSINESS WIRE)--Sep. 16, 2025-- Tandem Diabetes Care® (NASDAQ: TNDM), a global insulin delivery
